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Abstract
Background: X-linked inhibitor of apoptosis protein (XIAP) is often overexpressed in cancer cells, where it plays a
key role in survival and also promotes invasiveness. To date however, the extracellular signals and intracellular
pathways regulating its expression and activity remain incompletely understood. We have previously showed that
exposure to each of the three TGF-b (transforming growth factor beta) isoforms upregulates XIAP protein content
in endometrial carcinoma cells in vitro. In the present study, we have investigated the clinical relevance of TGF-b
isoforms in endometrial tumours and the mechanisms through which TGF-b isoforms regulate XIAP content in
uterine cancer cells.
Methods: TGF-b isoforms immunoreactivity in clinical samples from endometrial tumours was assessed using
immunofluorescence. Two model cancer cell lines (KLE endometrial carcinoma cells and HeLa cervical cancer cells)
and pharmacological inhibitors were used to investigate the signalling pathways regulating XIAP expression and
activity in response to autocrine and paracrine TGF-b in cancer cell.
Results: We have found immunoreactivity for each TGF-b isoform in clinical samples from endometrial tumours,
localizing to both stromal and epithelial/cancer cells. Blockade of autocrine TGF-b signaling in KLE endometrial
carcinoma cells and HeLa cervical cancer cells reduced endogenous XIAP mRNA and protein levels. In addition,
each TGF-b isoform upregulated XIAP gene expression when given exogenously, in a Smad/NF-B dependent
manner. This resulted in increased polyubiquitination of PTEN (phosphatase and tensin homolog on chromosome
ten), a newly identified substrate for XIAP E3 ligase activity, and in a XIAP-dependent decrease of PTEN protein
levels. Although each TGF-b isoform decreased PTEN content in a XIAP- and a Smad-dependent manner, decrease
of PTEN levels in response to only one isoform, TGF-b3, was blocked by PI3-K inhibitor LY294002.
Conclusions: XIAP gene expression and function is positively regulated by exposure to the three TGF-b isoforms in
a Smad-dependent manner, similar to constitutive XIAP gene expression which depends on autocrine TGF-b/Smad
signalling.
Background
TGF-b (transforming growth factor-beta) is a major reg-
ulator of proliferation, survival, migration/invasion and
metastasis in cancer cells (reviewed in [1]). Upon ligand
binding, TGF-b receptor I (TGFb-RI) recruits and phos-
phorylates Smad2 and Smad3: phosphorylated Smad2 or
Smad3 then associate with Smad4 to form heterodimeric
complexes that translocate to the nucleus, where they
can trigger downstream transcriptional responses [2].
Apart from this canonical Smad signalling pathway,
TGF-beta can also activate ERK [3] and PI3-K [4] path-
ways. Most data concerning TGF-b signaling and func-
tion comes from studies focusing on TGF-b1. However,
three TGF-b isoforms have been identified in mamma-
lian cells: TGF-b1, TGF-b2a n dT G F - b3. The three
TGF-b isoforms can play redundant roles in cancer
cells. However, recent studies have shown that TGF-b
isoforms can differentially regulate cancer cell pheno-
type: in prostate cancer cells for example, TGF-b2, but
not TGF-b1, confers resistance to TNFa-induced apop-
tosis [5]. Similarly, TGF-b3, but not TGF-b1 or TGF-b2,
increase the invasiveness of endometrial carcinoma cells
in vitro [6].
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key antiapoptotic role in endometrial carcinoma cells.
This member of the inhibitor of apoptosis protein family
can directly inhibit caspases-3, -7, and -9 [6], and we
recently observed that XIAP protects endometrial carci-
noma cells against various proapoptotic agents, includ-
ing TGF-b [6], TNFa [7] and chemotherapeutic drugs
[8]. We have recently reported that exposure to each of
the three TGF-b isoforms increase XIAP protein levels
in endometrial carcinoma cells [6]. Our results sug-
gested that TGF-b isoforms differentially activate intra-
cellular signaling pathways in endometrial carcinoma
cell: indeed, only TGF-b3 activates PI3-K/Akt pathway
and increases XIAP protein levels in a PI3-K-dependent
manner in these cells [6]. The different molecular
mechanisms through which each TGF-b isoform
increases XIAP protein content thus remains to be
determined.
We have recently highlighted a new function for XIAP
in cancer cells, in promoting polyubiquitination and pro-
teasomal degradation of PTEN (phosphatase and tensin
homolog deleted on chromosome ten) [9]. PTEN is a cri-
tical tumour suppressor [10], which negatively regulates
pro-survival PI3-K/Akt pathway through its lipid phos-
phatase activity [11], and inhibits several regulators of
cell cycle progression, including MAPK superfamily
member ERK, through its protein phosphatase activity
[12]. XIAP-induced degradation of PTEN is thus one of
the mechanisms through which cancer cells can achieve
successful inactivation of PTEN tumour suppressor func-
tion. Cellular factors regulating XIAP-induced degrada-
tion of PTEN, however, remain to be identified. We have
showed that TGF-b3 induces XIAP-dependent degrada-
tion of PTEN [9]: since TGF-b1a n dT G F - b2a l s o
increase XIAP levels in cancer cells, but through
mechanisms different from TGF-b3 [6], we hypothesized
that, compared to TGF-b3, these isoforms would differ-
ently regulate XIAP-induced degradation of PTEN.
In the present study, we have used KLE endometrial
carcinoma cell line and HeLa cervical cancer cell line, a
widespread model for the study of cancer cell signaling
[13,14], to determine the molecular mechanisms respon-
sible for the upregulation of XIAP by each TGF-b iso-
form, as well as the consequence on XIAP-induced
degradation of PTEN. We have found that autocrine
TGF-b signalling as well as exposure to exogenous
TGF-b isoforms upregulate XIAP expression at the tran-
scriptional level, in a Smad/NF-B dependent manner,
and promote XIAP-induced proteasomal degradation of
PTEN.
Results
The three TGF-b isoforms are present in human endo-
metrial tumours.W eh a v ep r e v i o u s l ys h o w nt h a tT G F -
b3 immunoreactivity can be detected in clinical samples
from endometrial carcinoma patients [6]. In the present
study, we have found the presence of TGF-b1 and TGF-
b2 immunoreactivity in these clinical samples (Figure
1A), indicating that each TGF-b isoform is present in
the tumour microenvironment. Contrary to TGF-b3
immunoreactivity, which was detectable in normal as
well as grade I and grade II samples but not in grade III
samples [6], TGF-b1 and TGF-b2 immunoreactivity was
detectable throughout cancer progression, even in grade
III tumours (Figure 1A). Similar to TGF-b3 [6], TGF-b1
and TGF-b2 immunoreactivity was detectable in both
epithelial and stromal compartments of endometrial
tumours (Figure 1A), suggesting that both autocrine and
paracrine TGF-b signalling takes place in these tumours.
The hypothesis of autocrine TGF-b signaling in endo-
metrial tumours is strengthened by the observation that
endometrial carcinoma cell lines such as KLE constitu-
tively produces the precursor protein of all three TGF-b
isoforms in vitro (Figure 1B). Similar to KLE cells, HeLa
cervical cancer cells constitutively produced precursor
protein for each TGF-b isoform (Figure 1B), indicating
that production of more than one TGF-b isoform is not
a unique feature of endometrial cancer cells.
Autocrine and paracrine TGF-b signaling regulate
XIAP gene expression. We have previously reported that
TGF-b isoforms increase XIAP protein levels in endo-
metrial carcinoma cells [6] and we observed that each
TGF-b isoform also upregulates XIAP protein content
in HeLa cervical carcinoma cells (Figure 2A), indicating
that the regulation of XIAP protein levels by TGF-b is
not restricted to cancer cells from the endometrium.
However, the mechanisms through which TGF-b iso-
forms regulate XIAP protein content in cancer cells
remained unknown. In the present study, we have inves-
tigated these mechanisms. Given exogenously, each
TGF-b isoform increased XIAP transcript levels (Figure
2B), revealing that paracrine TGF-b signaling regulates
XIAP expression at the transcriptional level. In addition,
blockade of autocrine TGF-b signaling (as showed by
reduced levels of phosphorylated Smad2 (Figure 2D))
using neutralizing TGF-b antibody reduced endogenous
XIAP transcript (Figure 2C) and protein (Figure 2D)
levels. Similarly, treatment with ALK5 inhibitor
SB431542, which blocked constitutive TGF-b receptor I
kinase activity as shown by decreased levels of phos-
phorylated Smad2 (Figure 2F), also decreased XIAP
transcript (Figure 2E) and protein (Figure 2F) levels.
The latter results reveal that autocrine TGF-b signaling
constitutively regulates XIAP gene expression.
TGF-b isoforms similarly promote XIAP gene expres-
sion via Smad pathway. We have investigated the path-
ways mediating the upregulation of XIAP gene
expression in response to each TGF-b isoform in KLE
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Page 2 of 12Figure 1 The three TGF-b isoforms are present in human endometrial tumours.A )T G F - b1 and TGF-b2 immunoreactivity (green) was
determined in human endometrial carcinoma tissues grade I, II and III and normal endometrial tissue, using Cybrdi human endometrial tissue
array slides. Tissues were obtained by biopsies. Negative control staining was obtained by replacing primary rabbit anti-TGF-bantibodies with
normal rabbit antiserum. Hoechst dye was used to visualize nuclei (blue). Results shown are representative of 17 grade I tumour specimens, 33
grade II tumour specimens, 5 grade III tumour specimens and 3 normal endometrial specimens. Magnification: 400×. B) Autocrine synthesis of
each TGF-b isoform was determined in KLE endometrial carcinoma cells and HeLa cervical cancer cells using western blot. b-actin was used as a
loading control.
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Page 3 of 12Figure 2 Autocrine and paracrine TGF-b signaling regulates XIAP gene expression in a Smad-dependent manner.A - B )H e L ah u m a n
cervical cancer cell line and KLE human endometrial carcinoma cell line were treated with the indicated recombinant TGF-b isoforms (10 ng/
mL) or with vehicle, for 24 h. XIAP protein levels in treated HeLa cells were determined using western blot (A); XIAP mRNA levels in treated KLE
and HeLa cells were determined using RT-PCR, and results from densitometric analysis are presented (B). C-D) KLE and HeLa cells were treated
with 2 μg/mL anti-TGF-b neutralizing antibody or isotypic control antibody for 24 h, and XIAP mRNA levels were determined using RT-PCR (C)
whereas XIAP protein levels were determined using western blot (D). E-F) KLE and HeLa cells were treated with 50 μM ALK5 inhibitor SB431543
or vehicle for 24 h, and XIAP mRNA levels were determined using RT-PCR (E) whereas XIAP protein levels were determined using western blot
(F). In D,F), levels of phosphorylated Smad2 (P-Smad2) were determined to monitor the efficiency of TGF-b pathway inhibition. In all
experiments, b-actin or GAPDH were used as loading controls. Graphs represent mean ± SE of three independent experiments. * p < 0.05
compared to control-treated cells.
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Page 4 of 12cells. PI3-K inhibitor LY294002 (Figure 3A) or ERK
upstream kinase MEK1 inhibitor PD98059 (Figure 3B)
did not inhibit the upregulation of XIAP mRNA in
response to TGF-b isoforms, indicating that TGF-b-
induced upregulation of XIAP gene expression is PI3-K-
and ERK-independent. However, knockdown of Smad4
using RNAi blocked the upregulation of XIAP mRNA in
response to each TGF-b isoform (Figure 3C), indicating
that the upregulation of XIAP gene expression by exo-
genous TGF- isoforms is Smad-dependent. In addition,
we found that knockdown of Smad4 using RNAi
reduced endogenous levels of both XIAP mRNA (Fig-
ure3D) and protein (Figure 3E). Altogether, these results
indicate that autocrine as well as paracrine TGF-b-
induced signalling induces XIAP gene expression in a
Smad-dependent manner.
TGF-b isoforms decrease PTEN protein content in a
XIAP-dependent manner.W eh a v ep r e v i o u s l ys h o w n
that overexpression of XIAP induces polyubiquitination
and degradation of PTEN protein [9]. Therefore, we
hypothesized that through their role in the regulation of
XIAP gene expression (Figure 2-3), TGF-b isoforms reg-
ulate PTEN protein content in uterine carcinoma cells.
In agreement with this, we found that upregulation of
XIAP levels by each TGF-b isoform (Figure 2A) was
accompanied by an increase of polyubiquitination of
PTEN and a decrease of PTEN protein levels (Figure
4A). Pre-treatment of the cells with proteasome inhibi-
tor MG-132 prevented TGF-b isoforms from decreasing
PTEN protein content (Figure 4B), showing that TGF-b-
induced decrease of PTEN involves proteasome activity.
Further, we found that knockdown of XIAP using RNAi
before exposure to each TGF-b isoform prevented TGF-
b from decreasing PTEN protein levels (Figure 4C).
Altogether, these results reveal that each TGF-b isoform
negatively regulates PTEN content in uterine carcinoma
cells, in a XIAP-dependent manner.
TGF-b decreases PTEN protein content through iso-
form-specific pathways. We have investigated the signal-
ing pathways involved in downregulation of PTEN in
response to the different TGF-b isoforms. Since Smad
pathway is involved in the upregulation of XIAP gene
expression by TGF-b isoforms (Figure 3) and that TGF-
b regulates PTEN content in a XIAP-dependent manner
(Figure 4), we first investigated whether TGF-b regulates
PTEN content in a Smad-dependent manner. We found
that interference with Smad4 RNA prevented each
TGF-b isoform from decreasing PTEN protein content
(Figure 5A). Then, blockade of ERK pathway activity
using PD98059, resulting in decreased levels of phos-
phorylated ERK (P-ERK), had no impact on TGF-b-
induced decrease of PTEN protein levels (Figure 5B).
However, pharmacological inhibition of PI3-K activity,
reflected by decreased levels of phosphorylated Akt
(P-Akt), prevented TGF-b3-induced, but not TGF-b1-
or TGF-b2-induced, reduction of PTEN protein content
(Figure 5C). These results indicate that TGF-b decreases
PTEN protein content in a Smad-dependent manner,
but also through isoform-specific pathways as only
TGF-b3 regulates PTEN content in a PI3-K-dependent
manner.
Smad and NF-B signaling pathway involvement in
TGF-b mediated XIAP upregulation. After verification of
the TGF-b mediated XIAP upregulation and concomi-
tant decrease in PTEN protein content, we investigated
whether this signal is predominantly delivered via Smad-
dependent and/or Smad-independent pathways. In Hela
cells, TGF-b stimulation induced Smad2 and Smad3
phosphorylation. Total Smad2 and Smad3 levels were
not modulated by TGF-b isoforms (Figure 6A). We also
observed a similar increase in the phosphorylation/acti-
vation of Smad2 and Smad3 in KLE cells treated with
each TGF-b isoforms (data not shown). It is known that
IB-a phosphorylation leads to activation, nuclear
translocation and increase in transcriptional activity of
NF-B. In order to understand whether the XIAP upre-
gulation is mediated through the activation of NF-Bb y
TGF-b isoforms, we performed western blot analysis
with a phospho-specific antibody against IB-a.T G F - b
treatment resulted in rapid phosphorylation of IB-a
with no effect on total IB-a levels (Figure 6B). There-
fore, these results suggest that TGF-b induced XIAP
upregulation is mediated through a TGF- b/Smad/NF-
B pathway.
Discussion
In the past, most studies examining the role of TGF-b
in cancer progression have focused on TGF-b1 isoform.
However, a number of studies have shown that TGF-b2
and TGF-b3 are often expressed in human tumours
[15,16]. Furthermore, the different TGF-b isoforms can
sometimes differentially activate signaling pathways in
cancer cells, leading to isoform-specific effects on cellu-
lar phenotype [5,6]. Dissecting the differential pathway
activation and roles of TGF-b isoforms in cancer cells
could foster the identification of specific factors regulat-
ing key aspects of tumour progression.
We have found that similar to various other cancer
cell types [15,16], human endometrial tumours contain
the three TGF-b isoforms. Since the proteins are detect-
able in both the epithelial and stromal counterparts of
t h et u m o u r s ,t h e yc o u l db er e s p o n s i b l ef o ra u t o c r i n ea s
well as paracrine signalling in the microenvironment of
these tumours. We had previously shown that exposure
to TGF-b isoforms increases XIAP protein content in
endometrial carcinoma cells [6], and here we found that
the three TGF-b isoforms upregulate XIAP expression,
at the mRNA level, in these cells. TGF-b1h a d
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Page 5 of 12Figure 3 TGF-b isoforms promote XIAP gene expression via Smad and PI3-K pathways. A-C) Before KLE cells were treated with the
indicated recombinant TGF-b isoforms (10 ng/mL) or with vehicle for 24 h, they were pre-treated with 50 μM PI3-K inhibitor LY294002 or
vehicle for 1 h (A), 10 μM MEK1/ERK pathway inhibitor PD98059 or vehicle for 1 h (B) or Smad4 siRNA or control (scrambled) siRNA for 24 h (C).
Levels of XIAP mRNA were determined using RT-PCR and results from densitometric analysis are presented. In all experiments, b-actin or GAPDH
were used as loading controls. Levels of Smad4 protein, phosphorylated ERK (P-ERK) or phosphorylated Akt (P-Akt) were determined to monitor
the efficiency of Smad4 RNAi, MEK/ERK pathway inhibition or PI3-K inhibition, respectively. Graphs represent mean ± SE of three independent
experiments. *p < 0.05. D-E) KLE and HeLa cells were treated with control (scrambled) or Smad4 siRNA for 24 h and levels of XIAP mRNA (D)
and protein (E) were determined using RT-PCR (D) and western blot analysis (E). b-actin and GAPDH were used as loading controls.
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Page 6 of 12Figure 4 TGF-b isoforms-induced decrease of PTEN protein content is XIAP-dependent. A) KLE and HeLa cells were treated with the
indicated recombinant TGF-b isoforms (10 ng/mL) or with vehicle for 24 h. Levels of phosphorylated Smad2 (P-Smad2) were determined to
monitor the activation of Smad pathway by TGF-b isoforms. Levels of PTEN protein and its ubiquitination were determined using western blot.
Graphs represent densitometrical analysis of PTEN in Hela Cells. B) HeLa cells were pre-treated with 10 μM proteasome inhibitor MG-132 for 1 h
before they were treated with the indicated recombinant TGF-b isoforms (10 ng/mL) or with vehicle, for 24 h. Levels of PTEN protein were
determined using western blot. C) Before treatment with the indicated recombinant TGF-b isoforms (10 ng/mL) or with vehicle for 24 h, HeLa
cells were transfected with XIAP shRNA or control (scrambled) shRNA for 24 h. PTEN and XIAP protein levels were determined using western
blot. In all experiments, levels of phosphorylated Smad2 (P-Smad2) were determined to monitor the activation of Smad pathway by TGF-b
isoforms and b-actin was used as a loading control. Graphs represent mean ± SE of three independent experiments. * p < 0.05.
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Page 7 of 12previously been shown to in c r e a s eX I A Pg e n ee x p r e s -
sion [17], but the impact of TGF-b2a n dT G F - b3w e r e
unknown. Further, the present study revealed that auto-
crine TGF-b signaling constitutively promotes XIAP
gene expression. To our knowledge, this is the first time
a receptor-activated pathway responsible for endogenous
production of XIAP by cancer cells is identified. RNAi
has allowed us to determine that constitutive as well as
exogenous TGF-b-induced XIAP gene expression
involves Smad pathway. However, we have found no
consensus sequence for Smad binding in the promoter
of XIAP, suggesting that Smad transcription factors are
not directly responsible for the induction of XIAP gene
expression in response to TGF-b. It has been shown
that Smad and NF-B components interact and coop-
erate to regulate gene expression in response to TGF-b
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Figure 5 TGF-b isoforms decrease PTEN protein content through differential pathways. A-C) Before treatment with 10 ng/mL recombinant
TGF-b isoforms or with vehicle for 24 h, KLE cells were pre-treated with Smad4 siRNA or control (scrambled) siRNA for 24 h (A), 10 μM MEK1/ERK
pathway inhibitor PD98059 or vehicle for 1 h (B) or 50 μM PI3-K inhibitor LY294002 or vehicle for 1 h (C). Protein lysates used were identical to
the ones used in figure 3. Levels of PTEN protein were determined using western blot. Levels of Smad4 protein, phosphorylated ERK (P-ERK) or
phosphorylated Akt (P-Akt) were determined to monitor the efficiency of Smad4 RNAi, MEK/ERK pathway inhibition or PI3-K inhibition,
respectively. In all experiments, b-actin was used as a loading control. Graphs represent mean ± SE of three independent experiments. * p <
0.05.
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Page 8 of 12[18-20], and the role of NF-B in constitutive expression
of XIAP is well established [21]. In the present study we
also found that upon TGF-b treatment both the compo-
nents of Smad and NF-B pathway are activated. There-
fore, constitutive XIAP gene expression could be
regulated via a TGF-b/Smad/NF-B pathway.
The present study further demonstrates that regula-
tion of XIAP expression by TGF-b isoforms impacts
XIAP function in cancer cells, since each TGF-b isoform
promotes XIAP-dependent degradation of PTEN when
added exogenously. To produce this effect, the three
TGF-b isoforms share a requirement for Smad signaling
pathway, consistent with the observation that TGF-bs
increase XIAP content via Smad pathway. However,
decrease of PTEN protein levels in response to TGF-b3,
but not TGF-b1 or TGF-b2, also requires PI3-K activity,
in agreement with our observation that PI3-K activity is
involved in TGF-b3, but not TGF-b1o rT G F - b2-
induced upregulation of XIAP protein [6]. The reason
why PI3-K activity is required, in addition to Smad sig-
naling, for TGF-b3 to decrease PTEN protein levels is
unknown. Since Akt has been shown to phosphorylate
and stabilize XIAP protein [22], inhibition of PI3-K/Akt
activity could be sufficient to reduce the stability of
XIAP protein and its interaction with PTEN, leading to
decreased ubiquitination and degradation of PTEN [9].
Alternatively, PI3-K activity has been shown to promote
nuclear export of PTEN [23], which could favour inter-
action of PTEN with XIAP in the cytosol, thus promot-
ing XIAP-induced degradation of PTEN. In fact, PI3-K
Figure 6 TGF-b isoforms-induced phosphorylation/activation of Smad2, Smad3 and IB-a. HeLa and KLE cells (not shown) were treated
with the indicated recombinant TGF-b isoforms (10 ng/mL) or with vehicle for 15 min. Levels of phosphorylated Smad2 (P-Smad2) and
phosphorylated Smad3 (P-Smad3) were determined to monitor the activation of Smad pathway by TGF-b isoforms and levels of phosphorylated
IB-a was determined to examine the activation of NF-B pathway. In all experiments, b-actin was used as a loading control. Graphs represent
mean ± SE of three independent experiments. * p < 0.05 compared to control.
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Page 9 of 12and Smad pathways may interact to regulate TGF-b3-
induced degradation of PTEN protein, since phosphory-
lated Akt interacts with Smad3 and prevents its phos-
phorylation and translocation to the nucleus [24,25]. In
this scenario, balance between PI3-K and Smad pathway
activities would regulate XIAP expression and XIAP-
induced degradation of PTEN, and inhibition of one or
the other pathway would be sufficient to block TGF-b3-
induced decrease of PTEN protein levels. Above all, the
fact that only TGF-b3 induces PI3-K-dependent
decrease of PTEN protein levels highlights the isoform-
specific nature of TGF-b-induced post-transcriptional
regulation of PTEN content.
Conclusions
The present study highlights the presence of the three
TGF-b isoforms in clinical samples from endometrial
carcinoma, and emphasizes the presence of autocrine
TGF-b production and signaling in cancer cells. Auto-
crine TGF-b signaling constitutively regulates XIAP
gene expression, in a Smad-dependent manner. Further-
more, exogenous/paracrine TGF-b signaling also tran-
scriptionally upregulates XIAP content, in an isoform-
specific manner. Finally, upregulation of XIAP in
response to TGF-b regulates XIAP function on post-
transcriptional regulation of PTEN protein content, and
autocrine TGF-b signalling regulates compartmentaliza-
tion of PTEN, probably in a XIAP-dependent manner.
Altogether, these observations highlight a new role for
TGF-b signaling in the regulation of XIAP gene expres-
sion and function.
Methods
Cell lines and reagents. Human endometrial carcinoma
cell line KLE and human cervical cancer cell line HeLa
were purchased from ATCC. KLE cells were maintained
in DMEM-F12 medium without HEPES supplemented
with 10% FBS and 50 mg/mL gentamycin; HeLa cells
were maintained in DMEM-F12 medium supplemented
with 2% BGS and 50 mg/mL gentamycin. XIAP plasmid
constructs were a kind gift from Dr. Robert G. Korneluk
(University of Ottawa Eye Institute, Ottawa, Ont,
Canada). All antibodies were from Cell Signaling Tech-
nology (Beverly, MA, USA) except for mouse monoclo-
nal anti-actin antibody (Sigma, St-Louis, MO, USA),
goat anti-rabbit, HRP-conjugated antibody (Bio-Rad
Laboratories, Mississauga, ON, Canada), and anti-TGF-b
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Recombinant TGF-bs were purchased from Cal-
biochem (San Diego, CA, USA). LY294002 and
PD98059 were purchased from Cell Signaling Technol-
ogy. SB431542 was purchased from Sigma.
Immunofluorescence-based detection of TGF-b1a n d
TGF-b2 in clinical samples. Preparation and image
analysis was performed as previously described [6]. Spe-
cificity of anti-TGF-bantibodies had previously been
confirmed by checkerboard peptide blocking experi-
ments [26]. Briefly, the working dilution of each anti-
body (TGF-b1 (sc-146) and TGF-b2 (sc-90) from Santa
Cruz Biotechnology) was incubated with a 10-fold
excess of blocking peptide (Santa Cruz Biotechnology)
overnight at 4°C before staining. In all cases, staining
was abolished by homologous peptide but unaffected
by pre-incubation with peptides corresponding to other
isoforms [26].
Cell treatments. Cells were seeded in 6 well-plates at
the required density to reach approximately 60% con-
fluency after 24 h (0.2 × 10
6 KLE cells and 0.5 × 10
6
HeLa cells per well). The following day, medium was
changed and replaced with fresh media containing the
appropriate treatment.
Western blots. Equal amounts of total cell lysates or
subcellular fractions (as determined using Bio-Rad DC
protein assay) were separated onto 8-15% polyacryla-
mide gels and then transferred onto nitrocellulose mem-
branes (Bio-Rad). The membranes were blocked with
5% milk in PBS-0.05% Tween-20 for 1 h at RT, probed
with primary antibody (PTEN #9559; XIAP #2042; P-
ERK #4377; P-Akt (Ser-473) #7291; Akt #9272; Smad3
#9513; Smad4 #9515; TGF-bRI #3712; all antibodies
from Cell Signaling) overnight at 4°C, washed in PBS-
0.05% Tween-20 and incubated with horseradish peroxi-
dase-conjugated anti-rabbit secondary antibody (Bio-
Rad). Detection was performed using SuperSignal West
FemtoTM substrate (Pierce, Arlington Heights, IL,
USA), as described by the manufacturer.
RNA extraction and RT-PCR analysis.T o t a lR N A
was isolated from cells using Trizol Reagent (Invitro-
gen, Burlington, ON, Canada) according to manufac-
turer’s instructions. First strand cDNA was synthesized
from 0.4 μg RNA using MMLV reverse transcriptase
(Invitrogen). Primers for PCR amplification of XIAP
were 5′-gagaagatgacttttaacagttttga-3′ (sense) and 5′-
ttttttgcttgaaagtaatgactgtgt-3′ (antisense). Primers for
amplification of PTEN were 5′-accaggaccagaggaaact-3′
(sense) and 5′-gctagcctctggatttgacg-3′ (antisense). Pri-
mers for amplification of Smad4 were 5′-gttgatgga-
tacgtggaccc-3′ (sense) and 5′-acctttgcctatgtgcaacc-3′
(antisense). Primers for amplification of GAPDH were
5′-gtcagtggtggacctgacct-3′ (sense) and 5′-tgagcttga-
caaagtggtcg-3′ (antisense). PCR reactions were
conducted in a MJ Research Thermal cycler (model
PTC-100), using the following parameters: 30 sec. at
94°C, 30 sec. at 58°C, and 1 min. at 72°C, for 35 cycles
except for GAPDH (25 cycles). The reaction mixture
was size-separated on an agarose gel and visualized
using SYBR-SafeTM (Invitrogen) staining upon ultra-
violet transillumination.
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Page 10 of 12Transfection with siRNAs. Cells were seeded in 6-well
plates at a required density to reach approximately 60%
confluency in 24 h (0.2 × 10
6 KLE cells and 0.5 × 10
6
HeLA cells per well), and allowed to adhere overnight.
The day of experiment, TGF-bRI (5′-ggacccuucauua-
gaucgctt-3′ and 5′-gcgaucuaaugaagggucctc-3′), Smad4
(5′-ggucuuugauuugcgucagtt-3′ and 5′-cugacgcaaaucaaa-
gacctt-3′) or control (5′-acucuaucugcacgcugacuu-3′ and
5′-aagucagcgugcagauagagu-3′) siRNAs were mixed with
Mirus Trans-it TKO transfection reagent (Fisher Scienti-
fic, Ottawa, ONT, Canada) following supplier’si n s t r u c -
tions and added to the cells (100 nM working
concentration). After 8 h-transfection, medium was
replaced and plates were incubated for 16 additional
hours (total: 24 h) or 40 additional hours (total: 48 h),
as indicated in Figure legends, at 37°C before cells were
collected.
Transfection with shRNAs. Cells were seeded in 6-well
plates at the required density to reach approximately
60% confluency after 24 h. The day of transfection,
XIAP shRNAs shRNA (5′-GCCACGCAGTCTA-
CAAATTCT-3′) or control (scrambled) shRNA (all
shRNA inserted into pGeneClip (SABiosciences, Freder-
ick, MD, USA)) were added to cells using a ratio of 3.6
μL Fugene:1.2 μg DNA/well. After 8 h-transfection,
medium was replaced and plates were incubated for
40 additional hours (total: 48 h) at 37°C before cells
were collected.
Statistical analysis
Data were subjected to one-way ANOVA (PRISM soft-
ware version 3.03; GraphPad, San Diego, CA). Differ-
ences between experimental groups were determined by
the Tukey’s test. Statistical significance was accepted
when p < 0.05 and indicated as asterisk above individual
graph bars.
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